Sigida crystal drops Ch. 0.05% 10ml

$8.18

Sigida crystal drops Ch. 0.05% 10ml

Quantity:

SKU: 01064371190 Categories: , , Tag:

Description

Composition
Active substance:
1 ml of the preparation contains:
Naphazoline nitrate (Naphthyzinum) 0.5 mg.
Excipients:
Boric acid 18.7 mg, 1.125 mg of Macrogol 300, 1.0 mg of Sodium hyaluronate, Disodium edetate dihydrate (Trilon B) 0.5 mg, 1 M sodium hydroxide solution or nitric acid 0.1 M solution until pH 4,0 – 7.0
Water for injections to 1 mL.
Description:
Clear, colorless or slightly yellowish liquid.
Product form:
Eye drops 0.05%.
10 ml vial.
Contraindications
Hypersensitivity to the drug.
Closure glaucoma.
Children under 2 years old.
Carefully:
Severe cardiovascular disease (ischemic heart disease, arterial hypertension), pheochromocytoma, prostate hyperplasia, hyperthyroidism, diabetes, porphyria, sicca, keratoconjunctivitis sicca, glaucoma, combined use with monoamine oxidase inhibitors, or other means able to increase blood pressure.
Dosage
0.5 mg / ml
Indications
Symptomatic temporary relief secondary hyperemia (redness) of the eye due to the mild annoyance and allergic conjunctivitis.
Interaction with other drugs
Use of naphazoline simultaneously with the reception of tricyclic antidepressants can potentiate naphazoline vasoconstrictive action.
Concomitant use with naphazoline and monoamine oxidase inhibitors within 14 days after their withdrawal may lead to hypertensive crises.
When concomitant therapy with other local ophthalmic preparations should adhere to 15-minute interval between their use.
Overdose
The local application of the drug overdose unlikely. There are no data about overdose cases nafazolina in the dosage form of eye drops. Overdosing or accidental ingestion can cause central nervous system depression, hypothermia, heart rhythm disturbances, hyperhidrosis, prolonged mydriasis, drowsiness and coma (risk of overdose higher in children and elderly patients), increased blood pressure possibly followed by a sharp decrease in blood pressure, tachycardia .
Treatment – symptomatic.
pharmachologic effect
Pharmacological group:
Decongestant agent – alpha-agonists.
Pharmacodynamics:
Naphazoline stimulates alpha-2-adrenoceptors vessels, local application has vasoconstrictor effect that reduces the edema and hyperemia of the conjunctiva.
Pharmacokinetics:
Full naphazoline local effect is already apparent after 5 minutes from the time of application. Effect lasts for 6-8 hours. Naphazoline can be absorbed by the mucous membranes, causing systemic effects, although such action is in adults after administration into the conjunctival sac it is unlikely. Systemic reactions occur mainly in elderly patients and in young children.
Pregnancy and breast-feeding
Application of pregnancy and breastfeeding period is possible only if the expected benefit to the mother outweighs the potential risk to the fetus and child.
There are no data on excretion into breast milk nafazolina. In the case of caution during breastfeeding.
Conditions of supply of pharmacies
Without a prescription.
side effects
From a sight organ: burning, itching, pain in the eye area; Reactive hyperemia, visual disturbances, dryness of nasal mucosa, mydriasis, increased intraocular pressure.
Children and elderly patients are possible: pale skin, tachycardia, pain in the heart, increased blood pressure, sweating, tremor, headache, agitation, nausea, drowsiness, dizziness.
special instructions
The drug is intended for topical application. Use of the drug can cause mydriasis.
Should stop using the product and consult your doctor if no improvement is observed within 72 hours, or irritation or redness continue or worsen, or there is pain in the eyes or blurred vision.
To avoid direct contact of the product with contact lenses. It is recommended prior to use eyedrops remove contact lenses. To avoid contamination, do not touch the upper part of the package to all surfaces. In the case of color change or turbidity of the solution preparation is not suitable for use.
Applying drops to children from 2 to 6 years should be made with caution, only under medical supervision. Patients with severe cardiovascular diseases, such as coronary heart disease, hypertension, pheochromocytoma, and metabolic disorders (hyperthyroidism, diabetes), as well as patients who receive monoamine oxidase inhibitors or other drugs that can increase blood pressure, the drug should be used only when the expected benefit outweighs the potential risk. Very frequent use can lead to redness of the eye.
Sigidov crystal is advisable to apply only in the case of lung irritation of the eyes. The patient needs to know: – if, within 48 hours does not improve or irritation or redness continue or increase, discontinue using the product; -to if irritation or redness associated with serious diseases of the organ of vision (e.g., infection, foreign body or corneal chemical injuries), it is recommended to consult a doctor; -If there are intense pain in the eyes, headache, rapid loss of vision, sudden appearance of floating spots before the eyes, redness of eyes, pain in the light period, or in the eyes begins to divide in two, the doctor should contact immediately.
Do not apply eyedrops Sigidov crystal patients with epidermal-Fuchs’ dystrophy.
Effects on ability to drive vehicles and mechanisms in mind the possibility of disorder should refrain from driving and other activities potentially hazardous activities immediately after treatment.
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Topically in the conjunctival sac.
Adults and children over 6 years: 1-2 drops into the conjunctival sac eyes 2-3 times a day.
Children 2 to 6 years: 1 drop 1-2 times a day.
The drug should not be used longer than 3-5 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Grotex Ltd.

There are no reviews yet.

Add your review